Lucy Edwardes Jones

DefiniGEN is a game-changing company headquartered in Cambridge, UK, with a mission to navigate drug development programs through uncertain terrain, minimizing risk while reducing costs and paving the way for a more efficient and effective future in the field of drug discovery. Our technology is revolutionizing liver models for efficacy and toxicology screening, utilizing a platform that enables the large-scale generation of hepatocyte-like cells (HLCs) with functional relevance comparable to human primary cells. Our HLCs effectively simulate crucial aspects of disease pathophysiology across various liver conditions, providing a more accurate understanding for drug development. By integrating CRISPR/Cas9 technology, DefiniGEN replicates disease phenotypes catering to unmet needs for in vitro efficacy testing and enabling the study of previously inaccessible rare monogenic liver diseases. Our HLCs successfully replicate all aspects of hepatocyte pathophysiology, allowing them to replace primary liver cells in many aspects of toxicity testing. This breakthrough provides scientists with a reliable and consistent supply of highly functional hepatocytes for the first time.

BGF is the most active and influential investor in small and mid-sized businesses in the UK. An established and independent company, we have £2.5bn to support a range of growing companies – early-stage, growth-stage and quoted – across every region and sector in the UK and Ireland. BGF is a minority, non-controlling equity partner with a patient outlook, based on shared, long-term goals with the management teams we back. With a 150+ strong team, BGF offers an unparalleled international network of business leaders, sector experts and board-level non-executives. We also provide in-house support, including chair and senior executive selection and appointments. BGF UK: http://www.bgf.co.uk BGF Ireland: https://www.bgfireland.ie/

DefiniGEN is a game-changing company headquartered in Cambridge, UK, with a mission to navigate drug development programs through uncertain terrain, minimizing risk while reducing costs and paving the way for a more efficient and effective future in the field of drug discovery. Our technology is revolutionizing liver models for efficacy and toxicology screening, utilizing a platform that enables the large-scale generation of hepatocyte-like cells (HLCs) with functional relevance comparable to human primary cells. Our HLCs effectively simulate crucial aspects of disease pathophysiology across various liver conditions, providing a more accurate understanding for drug development. By integrating CRISPR/Cas9 technology, DefiniGEN replicates disease phenotypes catering to unmet needs for in vitro efficacy testing and enabling the study of previously inaccessible rare monogenic liver diseases. Our HLCs successfully replicate all aspects of hepatocyte pathophysiology, allowing them to replace primary liver cells in many aspects of toxicity testing. This breakthrough provides scientists with a reliable and consistent supply of highly functional hepatocytes for the first time.

BGF is the most active and influential investor in small and mid-sized businesses in the UK. An established and independent company, we have £2.5bn to support a range of growing companies – early-stage, growth-stage and quoted – across every region and sector in the UK and Ireland. BGF is a minority, non-controlling equity partner with a patient outlook, based on shared, long-term goals with the management teams we back. With a 150+ strong team, BGF offers an unparalleled international network of business leaders, sector experts and board-level non-executives. We also provide in-house support, including chair and senior executive selection and appointments. BGF UK: http://www.bgf.co.uk BGF Ireland: https://www.bgfireland.ie/